Top-end interventions featured in Scottish surgery guarantees:
This article was originally published in Clinica
Scottish plans to end the so-called "hidden waiting lists" of surgery patients should provide a boost to the most specialised interventions, some of which have, until now, been excluded from the lists altogether. So said cabinet secretary for health and wellbeing, Nicola Sturgeon, in an announcement to parliament concerning the new surgery management system that will replace Availabilty Status Codes (ASCs) by the end of this year. "Patients will no longer be excluded from waiting time guarantees because their treatment is considered either of low clinical priority or too highly specialised." She acknowledged that some patients have been facing waits of "months and, in some cases, years" for treatment; the new system will also be "fully transparent and open to public scrutiny".
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.